Researchers looked at the DNA of 560 different breast tumors and identified 93 different genes that can start a cell down the path to malignancy. Researchers say most of the common genes involved in breast cancer were identified, five of which were not previously connected to the disease.
Because the researchers were able to group the different cancers by which mutated genes caused the disease, medicines can be used that already target some of these genes, and new treatments can potentially be created.
All of this is part of what President Obama was hoping for when he launched his Precision Medicine Initiative—figuring out personalized medicines based on the unique characteristics of patients, as opposed to the way most cases are approached today, with the same treatments given to all patients with a specific disease.
As DNA sequencing becomes less expensive, the tumors of a greater number of people will be sequenced, hopefully leading to more and more specific treatments, with fewer side effects. (And let’s hope that any newly designed drugs won't be priced so high that patients can't make use of them.)
More Computing Power Applied
Finding these 93 genes was a herculean task. In fact, it could not have been done even a few years ago; because of the way cancer starts and progresses, the amount of DNA sequencing and the computational power necessary is extraordinary.
Cancer begins when key parts of a cell’s DNA are altered. When the parts of our cells that fix this damage become broken -- due to our environment, health choices, or just bad luck -- that is where the trouble starts, as the mutations are now free to accumulate in a big way.
Most of those mutations, however, have nothing to do with the cell being cancerous. So, distinguishing the few "driver" mutations, the ones that contribute to the cancer, from the inconsequential "passenger" mutations is extremely time-intensive. The process is made even more complex due to the fact that not all of a tumor's cancer cells share the same mutations.